5 Health Canada's approval of this indication is based on the results of the SOUL trial
However, the incidence and prevalence of MetS or associated risk factors such as insulin resistance, hypertension, LDL-cholesterol, obesity, or large abdominal circumference are higher in vitiligo patients (Ata and Gnl, 2017
Conclusion GLP-1 receptor agonists like semaglutide and tirzepatide, and investigational agents like retatrutide, are transforming metabolic care
Key Takeaways The FDA repeated its decision that the shortage of the blockbuster diabetes and weight loss drug tirzepatide is over The announcement means that compounding pharmacies must stop producing the drug by March 19 Other shortages of popular GLP-1 medications remain THURSDAY, Dec
Weight loss occurs because you eat fewer calories while feeling satisfied, not because your body burns significantly more energy